CAR-T-cell therapy against BrM-specific antigens could be further employed to overcome limitations potentially imposed by differences in molecular profiles between BrM and extracranial tumors, considering that extracranial tumors may be more “visible” to the immune system than tumors in the brain, and consequently the systemic anti-tumor responses may “overlook” key BrM-specific tumor antigens. This evidence concerns the gene SMARCA2 and neoplasm.